JNJ Johnson & Johnson - Fundamental Analysis
NEUTRAL
Sign in to save
Save to watchlist or track a position.
JNJ Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Drug Manufacturers - General
Current Price
Live
$218.66
Analyst Target
$212.0
-3.0%
Downside
52W High
$220.11
52W Low
$141.5
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Confidence
75%
Johnson & Johnson's Advanced Deterministic Scorecard reveals a weak financial health signal with a Piotroski F-Score of 3/9, indicating significant operational or balance sheet concerns. Despite strong profitability metrics like a 33.62% ROE and solid earnings growth, the low Piotroski score, bearish technical trend, and negative insider activity offset these strengths. The stock trades above its Graham Number of $87.55 but below the growth-based intrinsic value of $305.03, suggesting a fair valuation given moderate growth expectations. However, weak liquidity ratios and lack of Altman Z-Score data prevent a more bullish stance.
Key Strengths
Exceptional profitability with ROE of 33.62% and operating margin of 30.20%, well above sector averages
Strong year-over-year earnings growth of 91.00% and consistent quarterly earnings beats (3 out of last 4)
Defensive dividend profile with a sustainable 49.08% payout ratio and 2.37% yield
Significant market leadership with a $526.82B market cap in the stable healthcare sector
Revenue growth of 6.80% outpaces peers like Merck and Thermo Fisher despite macro challenges
Key Risks
Very low Piotroski F-Score of 3/9 signals deteriorating financial health and potential earnings quality issues
Weak liquidity position with a current ratio of 1.07 and quick ratio of 0.71, below safe thresholds
Bearish insider sentiment with $39.75M in net officer sales and zero buys in the last 6 months
Technical trend score of 10/100 indicates strong near-term price weakness or distribution
Missing key financial data (Altman Z-Score, ROIC, cash/debt figures) limits confidence in solvency assessment
AI Fair Value Estimate
Based on comprehensive analysis
$260.0
+18.9% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare JNJ against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning JNJ from our newsroom.
Newest → oldest
No matching news yet.